Complex Dosage CDMO HENNIG Arzneimittel offers contract manufacturing and development services with a special focus on complex solid dosage forms for modified release. Capabilities include tableting, coating, dry and wet granulation, extrusion, pelletising, dry-coated tablets and capsule filling, as well as blistering and secondary packaging, with easy scale‑up from lab to industrial scale. This positions them as a potential partner for pharmaceutical companies seeking end‑to‑end CDMO support from feasibility studies to full service.

OTC Consumer Growth The company is expanding a rapidly growing range of over‑the‑counter drugs, devices and food supplements, underscoring a consumer‑oriented business. This creates opportunities for co‑brand manufacturing, private label partnerships, or distribution collaborations with pharmacies, retailers and online platforms seeking EU‑based OTC and supplement manufacturing capabilities.

Therapeutic Focus HENNIG concentrates on vertigo, sleep disorders and hypertension, alongside a broad portfolio of generics and other therapeutic areas. For potential partners with products in these indications, there are possibilities for licensing, contract manufacturing for specialty formulations, or joint development of modified‑release versions and related delivery systems.

EU Market Access Based near Frankfurt with existing cross‑border collaboration (for example with Goodwill Pharma), HENNIG can serve as a EU manufacturing and distribution hub. This presents a pathway for regional supply agreements, licensing deals, or co‑marketing arrangements to reach EU markets efficiently.

Growth and Capabilities As a mid‑sized company with 51–200 employees and a dedicated 66‑strong sales force, HENNIG demonstrates room to scale production and expand commercial reach. Leveraging their tech stack and data capabilities, there are opportunities to offer integrated manufacturing analytics, digital supply chain optimization, and enhanced service levels to prospective customers.